Successes, failures mark 30 years of HIV/AIDS research

It is difficult to put your finger on why, almost exactly three decades after the first case of AIDS was reported, there is now a general feeling in the scientific community that big breakthroughs are coming soon in AIDS vaccines, treatments and prevention. It is not only that big financiers like the Bill & Melinda Gates Foundation are contributing millions to the eradication of HIV (although that certainly helps). It's that the 30 years spent on understanding the virus that causes AIDS is at last making sense in a coherent way. Read the report

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.